RET-Positive Metastatic NSCLC
WCLC 2022 on the Phase 3 SANOVO Study: Savolitinib or Placebo in Combination With Osimertinib in EGFRm and MET Overexpressed NSCLC
By
WCLC 2022 Conference Coverage
FEATURING
Qing Zhou
By
WCLC 2022 Conference Coverage
FEATURING
Qing Zhou
Login to view comments.
Click here to Login
